Evotec SE (EVO) Cash & Current Investments (2009 - 2026)
Evotec SE (EVO) reported Cash & Current Investments of $520704.3 for Q1 2026, up 33.27% on a YoY basis from $390715.1 in Q1 2025, and up 667.39% sequentially from $67853.9 in Q4 2025.
Evotec SE (EVO) Cash & Current Investments (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 10 years of Cash & Current Investments data on file, last reported at $520704.3 in Q1 2026.
- For the quarter ending Q1 2026, Cash & Current Investments rose 33.27% year-over-year to $520704.3; the trailing twelve-month figure through Mar 2026 stood at $520704.3 (up 33.27% YoY), and the FY2025 full-year result was $67853.9, down 99.98% from the prior year.
- Cash & Current Investments grew to $520704.3 in Q1 2026, from $67853.9 in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $465.3 billion in Q1 2024 to a low of $67853.9 in Q4 2025.
- A 5-year average of $55.5 billion and a median of $947417.2 in 2022 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments jumped 7151845.65% in 2022 and plunged 100.0% in 2025, its largest moves.
- Tracing EVO's Cash & Current Investments over 5 years: stood at $733.0 million in 2022, then retreated by 11.33% to $650.0 million in 2023, then plunged by 48.92% to $332.0 million in 2024, then sank by 99.98% to $67853.9 in 2025, then jumped by 667.39% to $520704.3 in 2026.
- Business Quant data shows EVO's Cash & Current Investments at $520704.3 in Q1 2026, $67853.9 in Q4 2025, and $277379.4 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 2.15 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | 520,704.35 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 520,704.35 |
| Dec 31, 2025 | 67,853.86 |
| Sep 30, 2025 | 277,379.36 |
| Jun 30, 2025 | 393,923.10 |
| Mar 31, 2025 | 390,715.11 |
| Dec 31, 2024 | 331.99 Mn |
| Sep 30, 2024 | 254.02 Bn |
| Mar 31, 2024 | 465.30 Bn |
| Dec 31, 2023 | 649.99 Mn |
| Dec 31, 2022 | 733.04 Mn |
| Sep 30, 2022 | 830,483.30 |
| Jun 30, 2022 | 947,417.23 |
| Mar 31, 2022 | 959,392.24 |
| Dec 31, 2021 | 800.31 Mn |
| Sep 30, 2021 | 393.18 Bn |
| Jun 30, 2021 | 13.25 |
| Dec 31, 2020 | 516.60 Mn |
| Sep 30, 2020 | 79.43 |
| Dec 31, 2019 | 306.65 Mn |
| Sep 30, 2010 | 24.27 Bn |